AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction

Cancer Immunology, Immunotherapy

Volumn 63, Issue 11, 2014, Pages 1141-1150

  Perez, Sonia A ^a   Anastasopoulou, Eleftheria A ^a   Papamichail, Michael ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

AE37; DTH; HER 2 neu vaccine; IFN ; Prostate cancer; TGF

Indexed keywords

AE37 VACCINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

AGED; CLINICAL TRIAL; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANCER VACCINES; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84924928591     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1582-3     Document Type: Article

References (31)

1. Di Lorenzo G, Buonerba C, Kantoff PW (2011) Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:551–561. doi:10.1038/nrclinonc.2011.72
2. Cheng ML, Fong L (2014) Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 15:115–126. doi:10.1007/s11864-013-0267-z
3. May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW (2011) Prostate cancer immunotherapy. Clin Cancer Res 17:5233–5238. doi:10.1158/1078-0432.CCR-10-3402
4. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613. doi:10.1093/jnci/djs033
5. Baxevanis CN (2012) Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. Expert Rev Vaccines. 11:275–277. doi:10.1586/erv.11.193
6. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A (2002) Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8:1148–1154
7. Khor LY, Bae K, Paulus R et al (2009) MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 27:3177–3184. doi:10.1200/JCO.2008.19.8267
8. Travis MA, Sheppard D (2014) TGF-beta activation and function in immunity. Annu Rev Immunol 32:51–82. doi:10.1146/annurev-immunol-032713-120257
9. Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520. doi:10.1038/nrc1926
10. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER (1994) Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135:2240–2247. doi:10.1210/endo.135.5.7956947
11. Barrack ER (1997) TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31:61–70
12. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347–1350
13. Holmes JP, Benavides LC, Gates JD et al (2008) Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26:3426–3433. doi:10.1200/JCO.2007.15.7842
14. Lesterhuis WJ, Schreibelt G, Scharenborg NM et al (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60:249–260. doi:10.1007/s00262-010-0942-x
15. Lopez MN, Pereda C, Segal G et al (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27:945–952. doi:10.1200/JCO.2008.18.0794
16. Perez SA, Kallinteris NL, Bisias S et al (2010) Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 16:3495–3506. doi:10.1158/1078-0432.CCR-10-0085
17. Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397. doi:10.1093/jnci/djq310
18. Ishikawa T, Kokura S, Sakamoto N et al (2013) Whole blood interferon-gamma levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. Int J Cancer 133:1119–1125. doi:10.1002/ijc.28117
19. Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658
20. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080. doi:10.1002/cncr.24988
21. Sotiriadou NN, Kallinteris NL, Gritzapis AD et al (2007) Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 56:601–613. doi:10.1007/s00262-006-0213-z
22. Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN (2007) Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121:2031–2041. doi:10.1002/ijc.22936
23. Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN (2013) AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother 62:1599–1608. doi:10.1007/s00262-013-1461-3
24. Reyes D, Salazar L, Espinoza E et al (2013) Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 109:1488–1497. doi:10.1038/bjc.2013.494
25. Prud’homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87:1077–1091. doi:10.1038/labinvest.3700669
26. Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14:e218–e228. doi:10.1016/S1470-2045(12)70582-X
27. de Vries IJ, Bernsen MR, Lesterhuis WJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787. doi:10.1200/JCO.2005.06.478
28. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290–10295. doi:10.1073/pnas.161260098
29. Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93–101. doi:10.1016/j.imlet.2006.08.002
30. Nacher M, Blazquez AB, Shao B, Matesanz A, Prophete C, Berin MC, Frenette PS, Hidalgo A (2011) Physiological contribution of CD44 as a ligand for E-selectin during inflammatory T-cell recruitment. Am J Pathol 178:2437–2446. doi:10.1016/j.ajpath.2011.01.039
31. Singh SK, Tummers B, Schumacher TN et al (2013) The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother 62:489–501. doi:10.1007/s00262-012-1351-0